Vizsgálati helyszín
Brain Research Center Amsterdam B.V.
Amsterdam, 1081 GN, HollandiaMég nincs intézményhez kötve
- 18futó vizsgálat
- 16lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 34 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 2. fázis13 vizsgálat
- 3. fázis11 vizsgálat
- 1. fázis7 vizsgálat
- 2/3. fázis2 vizsgálat
- 1/2. fázis1 vizsgálat
- Állapot
- Lezárult16 vizsgálat
- Toboroz9 vizsgálat
- Fut, nem toboroz5 vizsgálat
- Még nem toboroz4 vizsgálat
- Fő szponzor
- Hoffmann-La Roche4 vizsgálat
- Alnylam Pharmaceuticals2 vizsgálat
- Biogen2 vizsgálat
- Bristol-Myers Squibb2 vizsgálat
- F. Hoffmann-La Roche AG2 vizsgálat
- és még 21
Futó vizsgálatok
Toboroz
Study to Test Effects and Safety of RO7568282 in Early Parkinson's Disease
NCT07781644· 2. fázis· Hoffmann-La Roche· Forrás
Toboroz
Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight
NCT07770841· 3. fázis· Novo Nordisk A/S· Forrás
Toboroz
Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease
NCT07404865· 3. fázis· Vor Biopharma· Forrás
Toboroz
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants With Early Alzheimer's Disease
NCT07328451· 1. fázis· Denali Therapeutics Inc.· Forrás
Fut, nem toboroz
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
NCT07170150· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease
NCT07214727· 1. fázis· Alnylam Pharmaceuticals· Forrás
Toboroz
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473· 3. fázis· Boehringer Ingelheim· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
NCT06976203· 3. fázis· Bristol-Myers Squibb· Forrás
Toboroz
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
NCT07033494· 2. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
NCT06976216· 3. fázis· Bristol-Myers Squibb· Forrás
Toboroz
A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease
NCT06976268· 2/3. fázis· Biohaven Therapeutics Ltd.· Forrás
Toboroz
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
NCT06677060· 3. fázis· AstraZeneca· Forrás
Toboroz
A Phase 2a, dose-finding, randomized, double-blinded, placebo-controlled study to Evaluate the Pharmacodynamics, Pharmacokinetics, and Safety of Efavirenz in Patients with Early Alzheimer’s Disease
2023-509613-37-01· 1/2. fázis· Amsterdam UMC· Forrás
Toboroz
A study to test the biological properties of RO7568282 and whether it is safe in healthy participants and participants with Parkinson’s disease.
2024-511110-21-00· 1. fázis· F. Hoffmann-La Roche AG· Forrás
Fut, nem toboroz
Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)
NCT05531526· 3. fázis· AriBio Co., Ltd.· Forrás
Fut, nem toboroz
A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age
NCT05399888· 2. fázis· Biogen· Forrás
Toboroz
A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD
NCT05231785· 1. fázis· Alnylam Pharmaceuticals· Forrás
Fut, nem toboroz
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001
NCT01760005· 2/3. fázis· Washington University School of Medicine· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Lezárt vizsgálatok
Lezárult
A clinical trial to learn about the effects of VHB937 in people with Alzheimer's disease
2024-516966-12-00· 2. fázis· Novartis Pharma AG· Forrás
Fut, nem toboroz
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD)
NCT07234942· 1. fázis· Hoffmann-La Roche· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
NCT07174310· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT06966401· 3. fázis· Neurocrine Biosciences· Forrás
Lezárult
A Phase 2 Randomized, Placebo-Controlled, Double-Blind, Parallel-group Study to Evaluate the Efficacy and Safety of MK-1167 as Adjunctive Therapy in Participants with Mild to Moderate Alzheimer’s Disease Dementia
2024-515539-31-00· 2. fázis· Merck Sharp & Dohme LLC· Forrás
Lezárult
EFFICACY AND SAFETY OF GSK4527226 [AL101] IN PATIENTS WITH EARLY ALZHEIMER’S DISEASE
NCT06079190· 2. fázis· Glaxosmithkline Research & Development Limited· Forrás
Lezárult
Study to Assess Safety and Efficacy of PRI-002 in Patients With MCI to Mild Dementia Due to Alzheimer's Disease (AD)
NCT06182085· 2. fázis· PRInnovation GmbH· Forrás
Lezárult
Randomised, double-blind, placebo-controlled study to assess safety and efficacy of PRI-002 in patients with MCI or mild dementia due to Alzheimer’s disease (AD)
2022-503148-41-00· 2. fázis· Prinnovation GmbH· Forrás
Lezárult
A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Dementia with Lewy Bodies (DLB)
2023-504373-20-00· 2. fázis· Eip Pharma Inc.· Forrás
Lezárult
A First in Human Study of IBC-Ab002 in Persons With Early Alzheimer's Disease (AD)
NCT05551741· 1. fázis· Immunobrain Checkpoint· Forrás
Lezárult
GV1001 Subcutaneous(SC) for the Treatment of Mild to Moderate Alzheimer's Disease (AD)
NCT05189210· 2. fázis· GemVax & Kael· Forrás
Lezárult
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7486967 in Participants with Early Idiopathic Parkinson’s Disease
2023-504412-14-00· 1. fázis· F. Hoffmann-La Roche AG· Forrás
Lezárult
A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80
NCT05348785· 2. fázis· Biogen· Forrás
Lezárult
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study with a Long-Term Extension Treatment Period to Assess the Efficacy and Safety of JNJ-63733657, an Anti-tau Monoclonal Antibody, in Participants with Early Alzheimer’s Disease
2022-501188-42-00· 2. fázis· Janssen - Cilag International· Forrás
Lezárult
A study to assess how ALZ-801 affects laboratory tests and symptoms of Alzheimer's disease in patients who have a specific genotype (APOE4).
2024-515858-25-00· 2. fázis· Alzheon Inc.· Forrás
Fut, nem toboroz
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
NCT04437511· 3. fázis· Eli Lilly and Company· Forrás
Hibát jelzek